These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
505 related articles for article (PubMed ID: 31613199)
1. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199 [No Abstract] [Full Text] [Related]
2. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372 [TBL] [Abstract][Full Text] [Related]
3. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365 [TBL] [Abstract][Full Text] [Related]
5. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765 [TBL] [Abstract][Full Text] [Related]
6. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855 [TBL] [Abstract][Full Text] [Related]
7. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850 [No Abstract] [Full Text] [Related]
9. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
10. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States. Cui J; Klepser DG; McAdam-Marx C J Manag Care Spec Pharm; 2021 Jul; 27(7):840-845. PubMed ID: 34185562 [No Abstract] [Full Text] [Related]
11. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377 [TBL] [Abstract][Full Text] [Related]
12. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting. Capehorn M; Hallén N; Baker-Knight J; Glah D; Hunt B Diabetes Ther; 2021 Feb; 12(2):537-555. PubMed ID: 33423240 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458 [TBL] [Abstract][Full Text] [Related]
17. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953 [TBL] [Abstract][Full Text] [Related]
20. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]